IQVIA (IQV) Expected to Post Earnings on Tuesday

IQVIA (NYSE:IQV) is projected to post its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect IQVIA to announce earnings of $3.25 per share and revenue of $4.37 billion for the quarter. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 9:00 AM ET.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same quarter last year, the business posted $2.81 EPS. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. On average, analysts expect IQVIA to post $11.56 EPS for the current fiscal year and $12.93 EPS for the next fiscal year.

IQVIA Price Performance

IQVIA stock opened at $265.72 on Tuesday. IQVIA has a 52 week low of $154.50 and a 52 week high of $277.40. The company’s 50 day moving average price is $261.23 and its two-hundred day moving average price is $213.85. The stock has a market cap of $43.74 billion, a P/E ratio of 32.97, a P/E/G ratio of 2.32 and a beta of 1.17. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

Insider Activity

In other news, insider W. Richard Staub sold 5,500 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This represents a 29.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James G. Berkshire sold 2,668 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the sale, the insider owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. The trade was a 19.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 15,581 shares of company stock worth $3,796,021. 1.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on IQV. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, September 12th. Barclays boosted their price objective on IQVIA from $275.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. JPMorgan Chase & Co. upped their price objective on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Mizuho raised their target price on IQVIA from $275.00 to $300.00 and gave the company an “outperform” rating in a research report on Wednesday, October 7th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research report on Thursday, July 9th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $276.00.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.